S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
AI Stock Caught Trading Under Secret Name (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
AI Stock Caught Trading Under Secret Name (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
AI Stock Caught Trading Under Secret Name (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
AI Stock Caught Trading Under Secret Name (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Price, News & Analysis

$80.47
-1.64 (-2.00%)
(As of 02/22/2024 ET)
Today's Range
$78.95
$82.99
50-Day Range
$70.55
$97.64
52-Week Range
$53.71
$98.40
Volume
966,308 shs
Average Volume
730,232 shs
Market Capitalization
$3.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$116.50

Axsome Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
44.8% Upside
$116.50 Price Target
Short Interest
Bearish
15.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.41mentions of Axsome Therapeutics in the last 14 days
Based on 35 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.30) to $1.02 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.69 out of 5 stars

Medical Sector

60th out of 934 stocks

Pharmaceutical Preparations Industry

21st out of 417 stocks


AXSM stock logo

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Stock Price History

AXSM Stock News Headlines

5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Q4 2023 Axsome Therapeutics Inc Earnings Call
Axsome Therapeutics (AXSM) Set to Announce Earnings on Tuesday
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/23/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AXSM
Employees
502
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$116.50
High Stock Price Target
$180.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+44.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-187,130,000.00
Pretax Margin
-89.75%

Debt

Sales & Book Value

Annual Sales
$270.60 million
Book Value
$2.52 per share

Miscellaneous

Free Float
35,727,000
Market Cap
$3.81 billion
Optionable
Optionable
Beta
1.21
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 56)
    Founder, Chairman, CEO & President
    Comp: $1.32M
  • Mr. Nick Pizzie CPAMr. Nick Pizzie CPA (Age 49)
    M.B.A., Chief Financial Officer
    Comp: $732.94k
  • Mr. Mark L. Jacobson (Age 41)
    COO & Secretary
    Comp: $784.66k
  • Mr. Hunter Murdock Esq. (Age 44)
    General Counsel & Secretary
    Comp: $735.39k
  • Dr. Amanda Jones Pharm.D. (Age 41)
    Senior Vice President of Clinical Development
  • Ms. Lori Englebert M.B.A. (Age 46)
    Executive Vice President of Commercial & Business Development
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Finance














AXSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price target for 2024?

11 brokers have issued 12-month target prices for Axsome Therapeutics' shares. Their AXSM share price targets range from $81.00 to $180.00. On average, they expect the company's stock price to reach $116.50 in the next twelve months. This suggests a possible upside of 44.8% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2024?

Axsome Therapeutics' stock was trading at $79.59 on January 1st, 2024. Since then, AXSM shares have increased by 1.1% and is now trading at $80.47.
View the best growth stocks for 2024 here
.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 7,490,000 shares, a drop of 10.0% from the January 15th total of 8,320,000 shares. Based on an average daily volume of 652,300 shares, the short-interest ratio is currently 11.5 days.
View Axsome Therapeutics' Short Interest
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings data on Monday, November, 6th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $0.08. The company had revenue of $57.79 million for the quarter, compared to analysts' expectations of $54.88 million. Axsome Therapeutics had a negative net margin of 88.41% and a negative trailing twelve-month return on equity of 68.33%. During the same period in the prior year, the company earned ($1.03) EPS.

What guidance has Axsome Therapeutics issued on next quarter's earnings?

Axsome Therapeutics updated its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $71.0 million-$71.0 million, compared to the consensus revenue estimate of $66.4 million.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.81%), BVF Inc. IL (4.19%), Point72 Asset Management L.P. (1.77%), Bellevue Group AG (1.34%), PFM Health Sciences LP (0.99%) and Avidity Partners Management LP (0.97%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXSM) was last updated on 2/23/2024 by MarketBeat.com Staff